Standout Papers

Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction afte... 2003 2026 2010 2018 3.3k
  1. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction (2003)
    Bertram Pitt, Willem J. Remme et al. New England Journal of Medicine
  2. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials (2022)
    Muthiah Vaduganathan, Kieran F. Docherty et al. The Lancet
  3. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial (2009)
    Marvin A. Konstam, James D. Neaton et al. The Lancet
  4. A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF) (2019)
    John J.V. McMurray, David L. DeMets et al. European Journal of Heart Failure
  5. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial (2021)
    Scott D. Solomon, Rudolf A. de Boer et al. European Journal of Heart Failure
  6. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction (2021)
    David D. Berg, Pardeep S. Jhund et al. JAMA Cardiology
  7. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF (2021)
    James P. Curtain, Kieran F. Docherty et al. European Heart Journal

Immediate Impact

2 by Nobel laureates 2 from Science/Nature 145 standout
Sub-graph 1 of 14

Citing Papers

From geroscience to precision geromedicine: Understanding and managing aging
2025 Standout
Heart failure with preserved ejection fraction: everything the clinician needs to know
2024 Standout
1 intermediate paper

Works of Felipe A. Martínez being referenced

SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
2022 Standout
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
2003 Standout

Author Peers

Author Last Decade Papers Cites
Felipe A. Martínez 4778 3756 1605 97 7.1k
Jean‐Jacques Mourad 3031 1823 1912 180 6.1k
Martina Brueckmann 4213 2452 1429 145 6.7k
Andrzej Januszewicz 2727 3137 2650 275 7.0k
Søren Lund Kristensen 2756 2509 1227 134 6.0k
Martin Lefkowitz 9713 2504 1542 171 12.3k
Victor Shi 11429 2926 1321 120 12.9k
Jacob A. Udell 3000 5196 2305 158 8.4k
John Vincent 2893 1673 773 74 4.4k
Harry Shi 2984 1838 892 56 4.5k
Michael Szarek 2204 3156 3713 120 7.0k

All Works

Loading papers...

Rankless by CCL
2026